checkAd

     161  0 Kommentare RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25

    TEL-AVIV, Israel and RALEIGH, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview at the Virtual Life Sciences Investor Forum on Thursday, June 25, 2020, at 10 a.m. EDT.

    This will be a live, online presentation where the audience is invited to ask the Company questions in real-time. The live broadcast and Q&A session can be accessed via the Company's website: http://ir.redhillbio.com/events. Please access the website at least 15 minutes ahead of the presentation to register.

    A replay of the presentation will be available for 30 days via the Company’s website: http://ir.redhillbio.com/events.           

    About RedHill Biopharma      
    RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs Movantikfor opioid-induced constipation in adults1, Talicia for the treatment of Helicobacter pylori (H. pylori) infection in adults2 and Aemcolo for the treatment of travelers’ diarrhea in adults3. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) Opaganib (Yeliva), a first-in-class SK2 selective inhibitor, targeting multiple indications, with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases. More information about the Company is available at www.redhillbio.com.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25 TEL-AVIV, Israel and RALEIGH, N.C., June 22, 2020 (GLOBE NEWSWIRE) - RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill's Chief Business Officer, …

    Schreibe Deinen Kommentar

    Disclaimer